Expand BBC Menu
BBC MENU

BBC ETF Profile


Family: Virtus ETF Solutions
Name: Virtus LifeSci Biotech Clinical Trials ETF
Inception Date: 17-Dec-2014
Termination Date:
Investment Objective: Virtus LifeSci Biotech Clinical Trials ETF is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the performance of the LifeSci Biotechnology Clinical Trials Index. Clinical Trials stage companies are typically younger, smaller companies which do not have a drug approved, but instead focus on testing their experimental drugs.
Prospectus
Top 10 Holdings
Viking Therapeutics Inc VKTX 2.9768%
Alpine Immune Sciences Inc ALPN 2.9379%
Avidity Biosciences Inc RNA 2.5224%
Vera Therapeutics Inc VERA 2.3379%
Spyre Therapeutics Inc SYRE 1.9885%
Apogee Therapeutics Inc APGE 1.9055%
Cullinan Oncology Inc CGEM 1.8072%
Dyne Therapeutics Inc DYN 1.8051%
Sana Biotechnology Inc SANA 1.7806%
Liquidia Corp LQDA 1.6353%
Top 10 Holdings Weight: 21.7%
Number of Holdings: 104
Shares Outstanding: 400,004
Total Net Assets: 10,150,180
NAV: 25.37
Net Expense Ratio: 0.79%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country: US
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry: Biotech
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: Broad Market / Multi-Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged: No
US or Ex-US: Domestic